Searchable abstracts of presentations at key conferences in endocrinology

ea0014p126 | (1) | ECE2007

Clinical and biochemical effects of adjuvant mitotane treatment in patients with adrenocortical cancer (ACC)

Daffara Fulvia , De Francia Silvia , Reimondo Giuseppe , Zaggia Barbara , Sperone Paola , Di Carlo Francesco , Angeli Alberto , Berruti Alfredo , Terzolo Massimo

Objective: Seventeen patients (9 women, 8 men aged 36 years, 22–58) radically resected for ACC were treated with adjuvant mitotane and prospectically followed from 2000 to 2006.Methods: Stage of ACC: was: 1 stage I,; 12 stage II, 4 stage III; Weiss score 6, 3–9; Ki67% 20, 4–67. Eleven patients had functional tumors. Median duration of treatment was 15 months (range:4–84) and 14 patients are currently on mitotane, 2 died, 1 discontinue...

ea0049ep26 | Adrenal cortex (to include Cushing's) | ECE2017

Assessment of the hypothalamic pituitary adrenal axis in patients receiving adjuvant mitotane treatment after radical resection of adrenocortical carcinoma

Reimondo Giuseppe , Puglisi Soraya , Zaggia Barbara , Basile Vittoria , Saba Laura , Perotti Paola , De Francia Silvia , Zatelli Maria Chiara , Cannavo Salvatore , Terzolo Massimo

Mitotane, used in the treatment of adrenocortical cancer (ACC), is able to inhibit multiple enzymatic steps of adrenocortical steroid biosynthesis, potentially causing adrenal insufficiency (AI). Recent studies in vitro have also documented a direct inhibitory effect of mitotane at the pituitary level.The aim of the study was to assess the hypothalamic pituitary adrenal (HPA) axis in patients receiving mitotane as adjuvant treatment after radica...

ea0020p188 | Endocrine tumours and neoplasia | ECE2009

Efficacy of repeat surgery in patients with recurrent adrenocortical cancer

Daffara Fulvia , De Francia Silvia , Ardito Arianna , Zaggia Barbara , Fiori Cristian , Angeli Alberto , Scarpa Roberto , Porpiglia Francesco , Perotti Paola , Berruti Alfredo , Terzolo Massimo

The optimal treatment of recurrent adrenocortical cancer (ACC) remains to be established since there are discrepant opinions on the value of repeat surgery. We did a retrospective analysis of the outcome of patients who were referred to our units from 1988 to 2006 for a recurrence of ACC, which occurred 2–83 years after radical removal of the tumor. In that period, the treatment policy of ACC recurrence differed among our units, since oncologists were more accustomed to u...

ea0056gp24 | Adrenal clinical | ECE2018

Germline CYP2W1*6 polymorphism is a new predictive marker of sensitivity to mitotane treatment in advanced adrenocortical carcinoma: a multicenter European study

Altieri Barbara , Herterich Sabine , Volante Marco , Sbiera Silviu , De Francia Silvia , Casa Silvia Della , Pontecorvi Alfredo , Quinkler Markus , Kienitz Tina , Mannelli Massimo , Canu Letizia , Chortis Vasileios , Kaltsas Gregory , Kroiss Matthias , Terzolo Massimo , Fassnacht Martin , Ronchi Cristina L

The cytochrome P450 2W1 (CYP2W1) is an orphan enzyme able to activate anticancer pro-drugs and to metabolise endogenous substances as fatty acids and lysophospholipids. Aim of the study was to evaluate the frequency of CYP2W1 polymorphisms in patients with adrenocortical carcinoma (ACC) and correlate it with the sensitivity to mitotane, which represents the only approved drug for the treatment of advanced ACC.Methods: A multicenter retrospective study in...